The Lab of Adaptive Immunity and Homeostasis

Happy to share a new story on a versatile technology allowing design of long-acting #antibodies with tailored target-dependent mode of actions. ⁦@NatureComms⁩ ⁦@UniOslo_MED⁩ ⁦@novonordiskfond⁩ ⁦@forskningsradet⁩ ⁩ @CoE_PRIMA nature.com/articles/s4146…

New study out in ⁦@NatureComms⁩! #FcRn biology-guided engineering of long-acting coagulation factor IX. ⁦@forskningsradet⁩ ⁦@Oslounivsykehus⁩ ⁦@UniOslo_MED⁩ nature.com/articles/s4146…

#Boston next week! Reach out to talk science and opportunities. #albumin #IgG #antibodies @AutheraAS @UniOslo @Oslounivsykehus @CoE_PRIMA fc-function-summit.com

Identification of a direct interaction between the Fab domains of IgG antibodies and human FcRn upon IgG-FcRn complex formation: Communications Biology, Published online: 12 June 2025; doi:10.1038/s42003-025-08252-zTwo orthogonal mass spectrometry… nature.com/articles/s4200…

The C-terminal end of #albumin can be cleaved, which reduces binding to #FcRn. As such, the plasma half-life drops from 3 weeks to about only 3-4 days in humans. This biology may have implications for design of the next generation of human albumin based therapeutics. @UniOslo_MED

In this review, we discuss the rise of #FcRn antagonists as a novel therapeutic class. @BioDrugsJournal link.springer.com/article/10.100… @UniOslo_MED @Oslounivsykehus

FcRn protects IgG and albumin from catabolism, transports IgG across the placenta, and regulates IgG function. Blocking or augmenting FcRn can decrease autoimmune antibodies and enhance drug delivery. Learn more in the Review Article “Neonatal Fc Receptor — Biology and Therapeutics” by James B. Bussel, MD, Douglas B. Cines, MD, and Richard S. Blumberg, MD, from @WeillCornell, the Perelman School of Medicine at the University of Pennsylvania, @BrighamWomens, and @harvardmed: nej.md/42gEZYk

New in JBC press: "Scientists' work describes an FcRn-driven mechanistic basis for induction of potent innate immune responses with a rHA-CpG conjugate design." Learn more: #sec-3" target="_blank" rel="nofollow noopener">jbc.org/article/S0021-…

Torleif Tollefsrud Gjølberg and colleagues describe FcRn biology, and give an overview of the current clinical pipeline of FcRn antagonists in autoimmune diseases. #neonatalFcReceptor #autoimmunedisease #OpenAccess link.springer.com/article/10.100…

Talenter og reisen! Les om Simones vei fra Forskerlinja på Ullern vg skole til ⁦⁦⁦@unioslo⁦@UniOslo_MED⁩ ⁩ ⁦⁦@Oslounivsykehus⁩ til CEO i ⁦@AutheraAS⁩. ⁦@ShareLabOslo⁩ ⁦@OsloSciencePark ⁦@OsloScienceCity⁩ skolesamarbeid.oslocancercluster.no/tidligere-ulle…

Listen to Careers in Discovery where ⁦⁦@TorleifGj⁩ , CSO and co-founder of ⁦@AutheraAS⁩ takes us through the company's journey from its academic beginnings ⁦@UniOslo_MED⁩ ⁦@UiO_LifeSci⁩ and ⁦⁦@Oslounivsykehus⁩ careers-in-discovery.podbean.com/e/torleif-gj%c…

We welcome Madicken Bildsten as a PhD student in our lab and @CoE_PRIMA🎈She will work on protein engineering strategies targeting cancer. Lab co-supervision by Nikoline Rasmussen and collaboration with the lab of @JOlweus 🔬@forskningsradet @UniOslo_MED @Oslounivsykehus

Thanks to Laura Tran from @TheScientistLLC for highlighting one of the recents scientific articles about #antibodies with pH-dependent antigen binding properties from @CAT4Science at @DTUtweet and @AndersenJT @UniOslo: the-scientist.com/ph-engineered-… Orig Article: cell.com/structure/full…

A warm welcome to our new lab member Lilli Bay! 🎈As a postdoc she will explore protein engineering strategies in the context of two favorite immune receptors; #FcRn and #TRIM21. Funded by @forskningsradet. @CoE_PRIMA @UniOslo_MED @OsloSciencePark @Oslounivsykehus

Proud of ⁦⁦⁦@AutheraAS⁩ and ⁦@SimoneMester_⁩ From master's degree to PhD to CEO in 2022. Simone is one of the winners of ⁦⁦@womentecheurope⁩! Thank you for the support. ⁦@forskningsradet⁩ ⁦⁦@OsloSciencePark⁩ medwatch.no/nyheter/karrie…

A seminar celebrating 🎈@DrRHatchett's honorary doctorate at @UniOslo_MED! @CEPIvaccines @CoE_PRIMA @Oslounivsykehus @Folkehelseinst @NFdep @Kunnskapsdep

@AaenKH has defended her PhD thesis “Next-generation human #albumin fusion proteins engineered for enhanced plasma half-life and therapeutic efficacy” You FIXed it! 🥊@UniOslo_MED @Oslounivsykehus @forskningsradet @CoE_PRIMA

Last week was fun 🎈 Mark Cragg in Oslo as Visiting Professor of @CoE_PRIMA. Engaging talks and discussions on immunotherapy and how to engineer #antibodies for agonism. @unisouthampton @UniOslo_MED @forskningsradet @NSImmun

On the cover of a magazine! 🎈Great collaboration with @AndreasLaustsen and the team🔬

Cool to see our article "Engineering of pH-dependent antigen binding properties for toxin-targeting IgG1 antibodies using light-chain shuffling" on the cover of @Structure_CP! #closeFullCover" target="_blank" rel="nofollow noopener">cell.com/issue/S0969-21… Read paper here: cell.com/structure/full…